Sitam 50/500 mg Tablets
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hankook Pharm Co., Ltd.
MFDS item code 201505752 · Approved 2015.08.18
This product's status changed to Approval withdrawn on 2025.02.12. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes
This medication is used in conjunction with diet and exercise therapy to help manage blood sugar levels in patients with type 2 diabetes. It can be used in cases where there is no prior experience with diabetes treatment or if blood sugar control is difficult with monotherapy. Additionally, this medication can be used as a substitute or in combination when metformin or sitagliptin alone is insufficient. It is used in conjunction with metformin when blood sugar control is difficult, even when combining with sulfonylureas or thiazolidinediones. In cases where blood sugar control remains inadequate while on insulin and metformin therapy, this medication can be added to improve treatment. Thus, this medication is used effectively to improve blood sugar control at various stages of treatment.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used to treat diabetes, and patients should be cautious as serious allergic reactions may occur during use. If skin rash, shortness of breath, or swelling of the face or lips occurs, discontinue use immediately and consult a doctor. Acute pancreatitis, an inflammation of the pancreas, may develop, so if abdominal pain, vomiting, or severe indigestion symptoms occur after taking this medication, seek medical attention immediately. This medication should not be used in patients with impaired kidney function, severe heart disease, liver dysfunction, or in pregnant or nursing women. Use of this medication should be temporarily discontinued before and after procedures involving iodine contrast agents and should only be resumed once normal kidney function is confirmed. This medication can cause hypoglycemia, especially when taken with other blood sugar-lowering agents, so blood sugar levels should be checked frequently, and symptoms of hypoglycemia should be monitored. Regular meals and exercise should be maintained, and this medication should be temporarily stopped in cases of sudden dehydration, severe infection, or pre/post-surgery. Alcohol intake can increase the risk of serious side effects such as lactic acidosis, so it is advisable to avoid drinking alcohol while on this medication. Regular blood tests should be conducted to monitor kidney function and vitamin B12 levels, and any abnormal symptoms should be discussed with healthcare providers. This medication carries a risk of reduced kidney function in the elderly, so dose adjustments and periodic function tests are necessary. In cases of overdose, immediate medical care should be sought as some drugs may be removed through dialysis. Irregular meals or intense exercise should be avoided during the course of this medication, and potential interactions with other medications should be discussed with healthcare providers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that allows for proper air circulation, kept at room temperature between 1°C and 30°C. This helps maintain the medication's effectiveness and safety.
Pink oval film-coated tablet
56 tablets (14 tablets/PTP packaging × 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hankook Pharm Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.